T
Thomas F. E. Barth
Researcher at University of Ulm
Publications - 239
Citations - 10830
Thomas F. E. Barth is an academic researcher from University of Ulm. The author has contributed to research in topics: Comparative genomic hybridization & Lymphoma. The author has an hindex of 49, co-authored 219 publications receiving 9570 citations. Previous affiliations of Thomas F. E. Barth include Heidelberg University & University of Würzburg.
Papers
More filters
Journal ArticleDOI
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
Michael Hummel,Stefan Bentink,Hilmar Berger,Wolfram Klapper,Swen Wessendorf,Thomas F. E. Barth,Heinz Wolfram Bernd,Sergio Cogliatti,Judith Dierlamm,Alfred C. Feller,Martin-Leo Hansmann,Eugenia Haralambieva,Lana Harder,Dirk Hasenclever,Michael Kühn,Dido Lenze,Peter Lichter,José I. Martín-Subero,Peter Möller,Hans Konrad Müller-Hermelink,German Ott,Reza Parwaresch,Christiane Pott,Andreas Rosenwald,Maciej Rosolowski,Carsten Schwaenen,Benjamin Stürzenhofecker,Monika Szczepanowski,Heiko Trautmann,Hans Heinrich Wacker,Rainer Spang,Markus Loeffler,Lorenz Trümper,Harald Stein,Reiner Siebert +34 more
TL;DR: The molecular definition of Burkitt's lymphoma clarifies and extends the spectrum of the WHO criteria for Burkitt’s lymphoma.
Journal ArticleDOI
T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance.
Ulrich Kintscher,Martin Hartge,Katharina Hess,Anna Foryst-Ludwig,Markus Clemenz,Martin Wabitsch,Pamela Fischer-Posovszky,Thomas F. E. Barth,Duska Dragun,Thomas Skurk,Hans Hauner,Matthias Blüher,Thomas Unger,Anna-Maria Wolf,Uwe Knippschild,Vinzenz Hombach,Nikolaus Marx +16 more
TL;DR: Proinflammatory T-lymphocytes are present in visceral adipose tissue and may contribute to local inflammatory cell activation before the appearance of macrophages, suggesting that these cells could play an important role in the initiation and perpetuation of adipOSE tissue inflammation as well as the development of IR.
Journal ArticleDOI
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
Heike Horn,Marita Ziepert,Claudia Becher,Thomas F. E. Barth,Heinz-Wolfram Bernd,Alfred C. Feller,Wolfram Klapper,Michael Hummel,Harald Stein,Martin-Leo Hansmann,Christopher Schmelter,Peter Møller,Sergio Cogliatti,Michael Pfreundschuh,Norbert Schmitz,Lorenz Trümper,Reiner Siebert,Markus Loeffler,Andreas Rosenwald,German Ott +19 more
TL;DR: A combined immunohistochemistry or FISH/immunohistochemical score predicts outcome in DLBCL patients independent of the IPI and identifies a subset of 15% of patients with dismal prognosis in the high-risk IPI group following treatment with R-CHOP.
Journal ArticleDOI
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.
Sandrine Sander,Lars Bullinger,Kay Klapproth,Katja Fiedler,Hans A. Kestler,Thomas F. E. Barth,Peter Möller,Stephan Stilgenbauer,Jonathan R. Pollack,Thomas Wirth +9 more
TL;DR: It is shown that ectopic expression of miR-26a influenced cell cycle progression by targeting the bona fide oncogene EZH2, a Polycomb protein and global regulator of gene expression yet unknown to be regulated by miRNAs, thereby vitally contributing to MYC-induced lymphomagenesis.